SAN DIEGO, Dec. 6 /PRNewswire/ -- Ceregene, Inc. today announced the
promotion of Raymond T. Bartus, Ph.D., to the position of executive vice
president of clinical and preclinical R&D and chief operating officer.
Since joining Ceregene in 2002, Dr. Bartus has led the preclinical and
clinical development efforts for CERE-120 and CERE-110, Ceregene's programs
for Parkinson's disease and Alzheimer's disease, respectively. These
efforts have included overseeing the development of well-designed Phase 2
clinical trial protocols as well as the management of clinical trial sites.
Dr. Bartus has also led the preclinical development efforts in our gene
therapy programs that target neurotrophic factors for the treatment of
amyotrophic lateral sclerosis (Lou Gehrig's disease) and ocular diseases.
Dr. Bartus formerly held the position of senior vice president of clinical
and preclinical R&D and chief operating officer.
"We are pleased to announce Ray's well-deserved promotion today, as he
has been a tremendous contributor and leader within Ceregene," stated
Jeffrey M. Ostrove, Ph.D., president and chief executive officer of
Ceregene. "Ray has been a key driver behind our CERE-120 and CERE-110
programs. His focused efforts have enabled us to move these promising
programs through clinical development, the furthest of which-CERE-120-could
enter Phase 3 trials for Parkinson's disease in 2009."
Dr. Bartus, a pioneer in the neuroscience industry, is the co-developer
of the Cholinergic Theory of Alzheimer's Disease -- a theory demonstrating
the relevance of cholinergic neurons in the disease process of Alzheimer's
disease, which is highly relevant to CERE-110, Ceregene's product candidate
for Alzheimer's disease as well as the majority of drugs on the market
today for Alzheimer's disease. Dr. Bartus brought nearly 30 years of
neuroscience expertise to Ceregene and has built and directed several
research teams at both large multi-national pharmaceutical companies and
small start-up companies. Under his leadership, his groups have
successfully identified and developed novel compounds, many of which have
advanced through clinical development and licensure. Additionally, Dr.
Bartus has maintained a strong scientific presence and continuous academic
affiliations during his career, which include adjunct academic appointments
and collaborations, editorial responsibility and a publication record
involving approximately 250 manuscripts. Dr. Bartus is the founding editor
and inaugural editor-in-chief of the scholarly journal, Neurobiology of
Aging: Experimental and Clinical Research.
Ceregene, Inc. is a San Diego-based biotechnology company focused on
the delivery of nervous system growth factors for the treatment of
neurodegenerative disorders using gene delivery. Ceregene's clinical
programs include CERE-110, an AAV2 based vector expressing nerve growth
factor that is currently in Phase 1/2 studies for the treatment of
Alzheimer's disease, and CERE-120 (AAV2-Neurturin) which recently completed
enrollment of a controlled Phase 2 study for Parkinson's disease. CERE-130
and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease)
and ocular disorders, respectively. Ceregene was launched in January 2001
and is a former subsidiary of Cell Genesys, Inc. (Nasdaq: CEGE). The
company's investors include Alta Partners, MPM Capital, Investor Growth
Capital and Cell Genesys as well as Hamilton BioVentures and California
SOURCE Ceregene, Inc.